83 FR 16436 - Notice of Intent To Grant an Exclusive License

DEPARTMENT OF VETERANS AFFAIRS

Federal Register Volume 83, Issue 73 (April 16, 2018)

Page Range16436-16437
FR Document2018-07844

Notice is hereby given that the Department of Veterans Affairs (VA), Office of Research and Development, Technology Transfer Program, intends to grant to Meiogen Biotechnology Corporation, 20 Assembly Square Drive, Somerville, MA 02145, an exclusive license to U.S. patent application No. 62/571,900 (``Compositions and Methods of Interferon Alpha Binding Proteins'') VA Invention Disclosure number 2018-010 titled, ``B18R (Normferon<SUP>TM</SUP>-alpha).'' The invention provides compositions comprising of interferon-alpha binding protein (B18R) and combined anti-retroviral therapy (cART) to treat HIV associated neurogenerative disorder (HAND). Ultimately, this invention provides a novel therapeutic option for subjects with HAND.

Federal Register, Volume 83 Issue 73 (Monday, April 16, 2018)
[Federal Register Volume 83, Number 73 (Monday, April 16, 2018)]
[Notices]
[Pages 16436-16437]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-07844]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF VETERANS AFFAIRS


Notice of Intent To Grant an Exclusive License

AGENCY: Department of Veterans Affairs.

ACTION: Notice of intent.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Department of Veterans Affairs 
(VA), Office of Research and Development, Technology Transfer Program, 
intends to grant to Meiogen Biotechnology Corporation, 20 Assembly 
Square Drive, Somerville, MA 02145, an exclusive license to U.S. patent 
application No. 62/571,900 (``Compositions and Methods of Interferon 
Alpha Binding Proteins'') VA Invention Disclosure number 2018-010 
titled, ``B18R (NormferonTM-alpha).'' The invention provides 
compositions comprising of interferon-alpha binding protein (B18R) and 
combined anti-retroviral therapy (cART) to treat HIV associated 
neurogenerative disorder (HAND). Ultimately, this invention provides a 
novel therapeutic option for subjects with HAND.

DATES: Comments must be received by May 1, 2018.

ADDRESSES: Written comments may be submitted through 
www.regulations.gov; by mail or hand-delivery to the Director, 
Regulations Management (02REG), Department of Veterans Affairs, 810 
Vermont Avenue NW, Room 1068, Washington, DC 20420; or by fax to (202) 
273-9026 (this is not a toll-free number). Copies of comments received 
will be available for public inspection in the Office of Regulation 
Policy and Management, Room 1063B, between the hours of 8:00 a.m. and 
4:30 p.m., Monday through Friday (except holidays). Call (202) 461-4902 
for an appointment (this is not a toll-free number). In addition, 
during the comment period, comments may be viewed online through the 
Federal

[[Page 16437]]

Docket Management System at www.regulations.gov.

FOR FURTHER INFORMATION CONTACT: Mr. Benjamin Henry, Technology 
Transfer Specialist, Office of Research and Development (10P9TT), 
Department of Veterans Affairs, 810 Vermont Avenue NW, Washington, DC 
20420, (202) 443-5736 (this is not a toll-free number).

SUPPLEMENTARY INFORMATION: It is in the public interest to license this 
invention. Meiogen submitted a complete and sufficient application for 
a license. The prospective exclusive license will be royalty-bearing 
and will comply with the terms and conditions of 35 U.S.C. 209 and 37 
CFR 404.7. The prospective exclusive license may be granted unless, 
within 15 days from the date of this published Notice, the Department 
of Veterans Affairs Office of Research and Development, Technology 
Transfer Program receives written evidence and argument which 
establishes that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    Signing Authority: The Secretary of Veterans Affairs, or designee, 
approved this document and authorized the undersigned to sign and 
submit the document to the Office of the Federal Register for 
publication electronically as an official document of the Department of 
Veterans Affairs. Jacquelyn Hayes-Byrd, Deputy Chief of Staff, 
Department of Veterans Affairs, approved this document on April 10, 
2018, for publication.

    Dated: April 10, 2018.
Jeffrey M. Martin,
Impact Analyst, Office of Regulation Policy & Management, Office of the 
Secretary, Department of Veterans Affairs.
[FR Doc. 2018-07844 Filed 4-13-18; 8:45 am]
 BILLING CODE 8320-01-P


Current View
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice of intent.
DatesComments must be received by May 1, 2018.
ContactMr. Benjamin Henry, Technology Transfer Specialist, Office of Research and Development (10P9TT), Department of Veterans Affairs, 810 Vermont Avenue NW, Washington, DC 20420, (202) 443-5736 (this is not a toll-free number).
FR Citation83 FR 16436 

2024 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR